CLINICAL TRIALS AND OBSERVATIONS Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

نویسندگان

  • Timothy P. Hughes
  • Andreas Hochhaus
  • Susan Branford
  • Martin C. Müller
  • Jaspal S. Kaeda
  • Letizia Foroni
  • Brian J. Druker
  • François Guilhot
  • Richard A. Larson
  • Stephen G. O’Brien
  • Marc S. Rudoltz
  • Manisha Mone
  • Elisabeth Wehrle
  • Vijay Modur
  • John M. Goldman
  • Jerald P. Radich
چکیده

1Department of Haematology, SA Pathology, Royal Adelaide Hospital, Adelaide, Australia; 2Abt Hämatologie und internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany; 3Molecular Pathology, SA Pathology, Adelaide, Australia and School of Medicine, University of Adelaide, Adelaide, Australia; 4III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; 5Department of Hematology, Central Hospital of Coimbra, Coimbra, Portugal; 6Haematology Department, Hammersmith Hospital, London, United Kingdom; 7Knight Cancer Institute, Oregon Health & Science University, Portland, OR; 8Centre d’Investigation Clinique CIC P 802, Inserm, Centre Hospitalier Universitaire de Poitiers, Poitiers, France; 9University of Chicago, Chicago, IL; 10Newcastle University Medical School, Newcastle, United Kingdom; 11Novartis Pharmaceuticals Corporation, East Hanover, NJ; 12Novartis Pharma AG, Basel, Switzerland; 13Novartis Institute of Biomedical Research, Cambridge, MA; and 14Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Regular Article CLINICAL TRIALS AND OBSERVATIONS Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio, Juan Luis Steegmann, Neil P. Shah, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiřı́ Mayer, Jorge Cortes, Michele Baccarani, Dong-Wook Kim, M. Brigid Bradley-Garelik, Hesham Mohamed, Mark Wildgust, and And...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) with clinical responses, event-free survival (EFS), and adverse events (AEs). Trough level plasma samples were obtained on day 29 (steady state, n 351). Plasma concentrations of imatinib and its metabolite CGP74588 were d...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

The Abl kinase inhibitor imatinib mesylate (STI571) has significant and rapid antileukemic activity in Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia (Ph ALL) but such activity is usually of short duration except for a small proportion of patients. To determine the prognostic significance of early Bcr-Abl levels and changes in peripheral blood (PB) and bone marrow (BM), s...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

We analyzed factors having an impact on response to treatment and survival in 78 consecutive patients with chronic myeloid leukemia (CML) in blastic transformation (BT) referred to the Hammersmith Hospital from January 1995 to December 2000. BT was defined as the presence of at least 30% blasts in blood or marrow or extramedullary blastic deposits. Immunophenotyping of blasts showed 57 myeloid,...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-

Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2010